Derivation Web

source_e9189d17f8e24af6

by researka:v2 · 2026-07-17 12:21:55.585022+04:00

# Research Synthesis: Longevity Lifespan Subgroups — full paper

## Abstract

This paper synthesizes evidence on longevity lifespan subgroups across 40 accepted source papers and 1449 high-confidence extracted claims.

The evidence profile contains 4 direct clinical sources, 36 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, with a high-density pairwise disagreement map across the evidence base.

Positive study-level signals are summarized in the mortality and survival outcome class, null signals in the contextual adjacent evidence, cardiometabolic and frailty outcome classes, and negative signals in the longevity outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that longevity lifespan subgroups remains a bounded evidence case: the retained direct, adjacent, and context evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified broad clinical claim.

In this section, the paragraph is tied to the local interpretive task. The recommendation-boundary safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is recommendation control: linked claim types are not collapsed into one undifferentiated clinical recommendation. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. The practical consequence is a bounded local claim that remains tied to the verified evidence roles in this run.

## Research Question

Within the retained source corpus for longevity lifespan subgroups, among adults, do findings for contextual adjacent evidence and longevity support a decision-grade conclusion (clinically actionable where applicable), and which population, study-design, and directness boundaries keep extrapolation to other outcome classes hypothesis-generating?

## Introduction

This synthesis evaluates evidence on longevity lifespan subgroups across 40 included source papers and 1449 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 4 direct clinical sources, 36 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

## Background

The background evidence for longevity lifespan subgroups is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Ramos 2026, Chang 2025, Wang 2024b are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation. [bundle:19] [bundle:29] [bundle:31]

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the mortality and survival outcome class; null signals around the contextual adjacent evidence, cardiometabolic and frailty outcome classes; and negative or adverse signals around the longevity outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

## Methods

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-longevity_lifespan_subgroups-v06-DAILY-2026-07-17T04-37-15Z-R2`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-17.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `longevity lifespan subgroups aging`
- `longevity lifespan subgroups older adults`
- `longevity lifespan subgroups randomized controlled trial`
- `longevity aging`
- `longevity older adults`
- `longevity randomized controlled trial`
- `lifespan aging`
- `lifespan older adults`
- `lifespan randomized controlled trial`

### Eligibility criteria
- Sources whose primary content addresses longevity lifespan subgroups.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 177 records in the receipt-candidate union, 57 were classified as source candidates and 40 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

### source admission funnel

| Admission bucket | n |
|---|---:|
| source candidate union | 177 |
| Classified source candidates | 57 |
| No extractable claims | 33 |
| None-only claim binding | 14 |
| Mixed partial-or-none claim-binding candidates | 50 |
| Partial-only claim-binding candidates | 16 |
| Strict high-confidence sources | 7 |
| Admitted final sources | 40 |

### Exclusion reasons
- No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Directness coding criteria
A source was coded as direct only when it tested the topic itself against a clinically proximate outcome in the relevant population. Human evidence with an adjacent exposure, population, or outcome was coded as indirect; syntheses and secondary reviews were coded as review-level evidence and were not counted as direct sources.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, frailty, immune and inflammation, longevity, mortality and survival, muscle function, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Evidence Landscape

### Findings Map

Findings Map completeness note: all 40 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |
| --- | --- | --- | --- | --- | --- | --- |
| Cardiometabolic | Lacy 2022: Comparison of cognitive function in older adults with type 1 diabetes, type 2 diabetes, and no diabetes: results from the Study of Longevity in Diabetes (SOLID) | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=24 extracted claim(s); source-level direction is the coded finding | [bundle:22]
| Cardiometabolic | Martini 2026: Early Biomarkers, Risk Factors, and Functional Indicators of Healthy Longevity and Their Relationship with Diet | direction=null | directness=indirect | B2 | outcome=Biomarker/Adjacent Cardiometabolic; direction=null | finding=16 extracted claim(s); source-level direction is the coded finding | [bundle:24]
| Cardiometabolic | Villaplana-Velasco 2025: Mendelian randomization study implicates inflammaging biomarkers in retinal vasculature, cardiovascular diseases, and longevity | direction=null | directness=indirect | B2 | outcome=Biomarker/Adjacent Cardiometabolic; direction=null | finding=15 extracted claim(s); source-level direction is the coded finding | [bundle:26]
| Cardiometabolic | Wu 2026: Time-restricted eating as a potential strategy for healthy lifespan: an evaluation of current evidence | direction=null | directness=indirect | B2 | outcome=Cardiometabolic; direction=null | finding=7 extracted claim(s); source-level direction is the coded finding | [bundle:33]
| Contextual Adjacent Evidence | Abdelraheem 2026: Genetic, Socioecological, and Health Research on Extreme Longevity in Semisupercentenarians and Supercentenarians: A Scoping Review | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=3 extracted claim(s); source-level direction is the coded finding | [bundle:35]
| Contextual Adjacent Evidence | Aliberti 2025: The Power of Environment: A Comprehensive Review of the Exposome’s Role in Healthy Aging, Longevity, and Preventive Medicine—Lessons from Blue Zones and Cilento | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=1 extracted claim(s); source-level direction is the coded finding | [bundle:37]
| Contextual Adjacent Evidence | Chen 2022: TOMM40 genetic variants associated with healthy aging and longevity: a systematic review | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=8 extracted claim(s); source-level direction is the coded finding | [bundle:32]
| Contextual Adjacent Evidence | Chevret 2026: Tissue-specific mitochondrial pathway remodeling linked to longevity in honeybee queens | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P ≤ 0.001; source-level statistic reported | [bundle:10]
| Contextual Adjacent Evidence | Gomez 2024: Longevity of dental restorations in Sjogren’s disease patients using electronic dental and health record data | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.002; source-level statistic reported | [bundle:17]
| Contextual Adjacent Evidence | Horton 2026: Relationship between antibody avidity, Fc-mediated functional activity and longevity of malaria vaccine responses in clinical trials | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.022; source-level statistic reported | [bundle:23]
| Contextual Adjacent Evidence | Hoshi 2026: Structural Relationships of Socioeconomic Factors Influencing Diet, Lifestyle Habits, Having a Dentist, and Health Factors That Impact Healthy Life Longevity for the Elderly | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=13 extracted claim(s); source-level direction is the coded finding | [bundle:27]
| Contextual Adjacent Evidence | Joshi 2025: Evidence-Based Pathways to Healthy Aging: A Systematic Review and Meta-analysis of Lifestyle Interventions for Longevity and Well-Being | direction=unclear | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=45 extracted claim(s); source-level direction is the coded finding | [bundle:11]
| Contextual Adjacent Evidence | Khalil 2025: Green Environments for Sustainable Brains: Parameters Shaping Adaptive Neuroplasticity and Lifespan Neurosustainability—A Systematic Review and Future Directions | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=13 extracted claim(s); source-level direction is the coded finding | [bundle:28]
| Contextual Adjacent Evidence | Kubo 2025: Physical activity associations with physical function and body composition among community‐dwelling older adults in Japan: The Kyotango Longevity Cohort Study | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.050; source-level statistic reported | [bundle:30]
| Contextual Adjacent Evidence | Lu 2024: Active longevity and aging: dissecting the impacts of physical and sedentary behaviors on longevity and age acceleration | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:4]
| Contextual Adjacent Evidence | Luo 2026: The effect of arteriovenous fistula longevity preservation exercise program combined with video-assisted patient education on fistula maturation for maintenance hemodialysis patients | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:20]
| Contextual Adjacent Evidence | Ramos 2026: Longevity of different in-office treatments for dentin hypersensitivity: A 6-month randomized and parallel clinical trial | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=representative nominally statistically significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded | [bundle:19]
| Contextual Adjacent Evidence | Reddy 2025: Battery longevity of a helix-fixation dual-chamber leadless pacemaker: results from the AVEIR DR i2i Study | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.05; source-level statistic reported | [bundle:14]
| Contextual Adjacent Evidence | Ribeiro 2025: Assessment of photobiomodulation combined with new restorative material for teeth with molar incisor hypomineralization on control of hypersensitivity and longevity of restorations: Protocol for a randomized controlled blind clinical trial | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=2 extracted claim(s); source-level direction is the coded finding | [bundle:36]
| Contextual Adjacent Evidence | Yuan 2026: A Weibull distribution-based method for estimating seed longevity in Solanum rostratum | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=representative statistic P < 0.05; source-level statistic reported | [bundle:15]
| Contextual Adjacent Evidence | Zhu 2025: Relationship between Sn elemental background values and regional longevity levels—Data from Yunnan, China | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.01; source-level statistic reported | [bundle:16]
| Frailty | Chen 2024: Sarcopenia in the era of precision health: Toward personalized interventions for healthy longevity | direction=null | directness=indirect | B2 | outcome=Frailty; direction=null | finding=6 extracted claim(s); source-level direction is the coded finding | [bundle:34]
| Frailty | Wang 2024b: Targeting Aging and Longevity with Exogenous Nucleotides (TALENTs): Rationale, Design, and Baseline Characteristics from a Randomized Controlled Trial in Older Adults | direction=null | directness=direct | A1 | outcome=Frailty; direction=null | finding=9 extracted claim(s); source-level direction is the coded finding | [bundle:31]
| Immune and Inflammation | Adibi 2026: A Conceptual Digital Health Framework for Longevity Optimization: Inflammation-Centered Approach Integrating Microbiome and Lifestyle Data—A Review and Proposed Platform | direction=unclear | directness=indirect | B2 | outcome=Immune and Inflammation; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:3]
| Immune and Inflammation | Chen 2019: Combined associations of hs-CRP and cognitive function with all-cause mortality among oldest-old adults in Chinese longevity areas: a prospective cohort study | direction=unclear | directness=indirect | B2 | outcome=Immune and Inflammation; direction=unclear | finding=76 extracted claim(s); source-level direction is the coded finding | [bundle:38]
| Immune and Inflammation | Qiu 2025: COVID-19 infection and longevity: an observational and mendelian randomization study | direction=unclear | directness=indirect | B2 | outcome=Immune and Inflammation; direction=unclear | finding=representative statistic P = 0.015; source-level statistic reported | [bundle:12]
| Longevity | Ajnakina 2023: Polygenic Propensity for Longevity, APOE -ε4 Status, Dementia Diagnosis, and Risk for Cause-Specific Mortality: A Large Population-Based Longitudinal Study of Older Adults | direction=mixed | directness=indirect | B2 | outcome=Longevity; direction=mixed | finding=representative statistic P = 0.010; source-level statistic reported | [bundle:5]
| Longevity | Barinda 2024: Repurposing effect of cardiovascular-metabolic drug to increase lifespan: a systematic review of animal studies and current clinical trial progress | direction=positive | directness=review | B1 | outcome=Mechanism/Longevity (animal/preclinical); direction=positive | finding=16 extracted claim(s); source-level direction is the coded finding | [bundle:25]
| Longevity | Chen 2026a: Modifiable risk factors attenuated longevity genetic predisposition on life expectancy in the oldest old | direction=positive | directness=indirect | B2 | outcome=Longevity; direction=positive | finding=representative statistic P = 0.040; source-level statistic reported | [bundle:7]
| Longevity | Chen 2026b: Healthy Lifestyle, multimorbidity network, and all-cause mortality among older Chinese: a longitudinal analysis in Chinese longitudinal healthy longevity survey | direction=negative | directness=indirect | B2 | outcome=Longevity; direction=negative | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:18]
| Longevity | Dai 2023: Combined associations of vitamin D and cognitive function with all-cause mortality among older adults in Chinese longevity areas: A prospective cohort study | direction=unclear | directness=indirect | B2 | outcome=Longevity; direction=unclear | finding=representative nominally statistically significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded | [bundle:13]
| Longevity | Gao 2024: Association of frailty with cardiovascular and all-cause mortality in community-dwelling older adults: insights from the Chinese longitudinal healthy longevity survey | direction=unclear | directness=indirect | B2 | outcome=Longevity; direction=unclear | finding=representative statistic P < 0.01; source-level statistic reported | [bundle:9]
| Longevity | Huang 2026: Life’s Essential 8 and healthy longevity among people with and without cardiometabolic multimorbidity: A prospective study of UK Biobank | direction=unclear | directness=indirect | B2 | outcome=Longevity; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:21]
| Longevity | Joshi 2017: Genome-wide meta-analysis associates HLA-DQA1/DRB1 and LPA and lifestyle factors with human longevity | direction=unclear | directness=review | B1 | outcome=Longevity; direction=unclear | finding=24 extracted claim(s); source-level direction is the coded finding | [bundle:40]
| Longevity | Wang 2024a: Association of changes in frailty status with the risk of all-cause mortality and cardiovascular death in older people: results from the Chinese Longitudinal Healthy Longevity Survey (CLHLS) | direction=mixed | directness=indirect | B2 | outcome=Longevity; direction=mixed | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:2]
| Longevity | Yokokawa 2023: How Long Would You Like to Live? A 25-year Prospective Observation of the Association Between Desired Longevity and Mortality | direction=mixed | directness=indirect | B2 | outcome=Longevity; direction=mixed | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:8]
| Mortality and Survival | Deelen 2014: Genome-wide association meta-analysis of human longevity identifies a novel locus conferring survival beyond 90 years of age | direction=positive | directness=review | B2 | outcome=Mortality and Survival; direction=positive | finding=representative statistic P = 0.003; source-level statistic reported | [bundle:39]
| Mortality and Survival | Liu 2025: Sources of income are associated with all-cause mortality risk in older people: results from the Chinese longitudinal healthy longevity survey (CLHLS) | direction=unclear | directness=indirect | B2 | outcome=Mortality and Survival; direction=unclear | finding=representative statistic P = 0.015; source-level statistic reported | [bundle:1]
| Muscle Function | Belenguer-Varea 2023: Effect of Familial Longevity on Frailty and Sarcopenia: A Case–Control Study | direction=unclear | directness=indirect | B2 | outcome=Muscle Function; direction=unclear | finding=representative statistic P = 0.001; source-level statistic reported | [bundle:6]
| Skeletal, Fracture, and Bone | Chang 2025: Effects of osteoporosis treatment and multicomponent integrated care on intrinsic capacity and happiness among rural community-dwelling older adults: the Healthy Longevity and Ageing in Place (HOPE) randomised controlled trial | direction=unclear | directness=direct | A1 | outcome=Skeletal, Fracture, and Bone; direction=unclear | finding=representative statistic P = 0.01; source-level statistic reported | [bundle:29]

## Results

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.


| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Longevity Lifespan Subgroups / Contextual Adjacent Evidence | n=17; claims=418 | significant source statistic in 10/17 sources; receipt-level direction coded unclear | 2 direct; 11 indirect; 4 review | limited corpus depth in this outcome class |
| Longevity Lifespan Subgroups / Longevity | n=10; claims=445 | significant source statistic in 8/10 sources; receipt-level direction coded unclear | 8 indirect; 2 review | limited corpus depth in this outcome class |
| Longevity Lifespan Subgroups / Cardiometabolic | n=4; claims=62 | no extracted directional signal in 3/4 sources | 4 indirect | limited corpus depth in this outcome class |
| Longevity Lifespan Subgroups / Immune and Inflammation | n=3; claims=192 | significant source statistic in 2/3 sources; receipt-level direction coded unclear | 3 indirect | limited corpus depth in this outcome class |
| Longevity Lifespan Subgroups / Frailty | n=2; claims=15 | no extracted directional signal in 2/2 sources | 1 direct; 1 indirect | limited corpus depth in this outcome class |
| Longevity Lifespan Subgroups / Mortality and Survival | n=2; claims=247 | significant source statistic in 2/2 sources; receipt-level direction coded unclear | 1 indirect; 1 review | limited corpus depth in this outcome class |
| Longevity Lifespan Subgroups / Muscle Function | n=1; claims=59 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 indirect | single-source slice; hypothesis-generating |
| Longevity Lifespan Subgroups / Skeletal, Fracture, and Bone | n=1; claims=11 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 direct | single-source slice; hypothesis-generating |

**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.
- Aging and geroscience context: 35 sources; significant source statistic in 22/35 sources; receipt-level direction coded unclear.
- Infectious-disease and immunology context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded unclear.
- Skeletal and muscle context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded unclear.

### Results Summary

- Contextual Adjacent Evidence: n=17; claims=418; mixed signal in 9/17 sources | directness: 2 direct; 11 indirect; 4 review; main limitation: directionally heterogeneous.
- Longevity: n=10; claims=445; mixed signal in 6/10 sources | directness: 8 indirect; 2 review; main limitation: no direct clinical anchor.
- Cardiometabolic: n=4; claims=62; no extracted directional signal in 3/4 sources | directness: 4 indirect; main limitation: no direct clinical anchor.
- Immune and Inflammation: n=3; claims=192; mixed signal in 3/3 sources | directness: 3 indirect; main limitation: no direct clinical anchor.
- Frailty: n=2; claims=15; no extracted directional signal in 2/2 sources | directness: 1 direct; 1 indirect; main limitation: population and endpoint heterogeneity.
- Mortality and Survival: n=2; claims=247; mixed signal in 1/2 sources | directness: 1 indirect; 1 review; main limitation: no direct clinical anchor.

### Cardiometabolic Outcomes


Four cohort-level studies populate the cardiometabolic evidence base for the longevity/lifespan-subgroups question, and none of them reports a within-corpus randomized comparison. Lacy 2022 is an observational cohort that compared baseline cognitive function and low cognitive function by diabetes status across n=734 T1D, n=232 T2D, and n=247 without-diabetes older adults in the Study of Longevity in Diabetes (SOLID), framing cardiometabolic subgroup stratification as the analytic backbone for aging outcomes. [bundle:22]

Quantitative findings across the cardiometabolic set are sparse and effect directions are predominantly null. No source in this outcome class supplies a p-value, hazard ratio, or odds ratio.

Mechanistically, the mechanistic substrate underlying these mixed cardiometabolic findings converges on inflammaging and metabolic substrate cycling as candidate pathways linking diabetes, adiposity, and time-restricted feeding to late-life function. Preclinical data and Mendelian-randomization designs (Villaplana-Velasco 2025) implicate inflammaging biomarkers in retinal vasculature, cardiovascular disease, and longevity, while mechanistic human studies and clinical RCT evidence synthesized by Wu 2026 describe metabolic improvements from time-restricted eating that could plausibly modify cardiovascular aging trajectories. Lacy 2022 adds a clinical-observation perspective by stratifying older adults across diabetes subgroups, providing an empirical scaffold for testing whether inflammaging pathways express differently by diabetes subtype — a question the mechanistic literature has not yet resolved. [bundle:22] [bundle:26] [bundle:33]

Within-corpus tensions across this outcome class are not declared as pairwise disagreements in the supplied cross-study disagreement map, but directional heterogeneity is visible across sources: Lacy 2022 carries an unclear effect direction while Martini 2026, Wu 2026, and Villaplana-Velasco 2025 each carry a null effect direction for the cardiometabolic-to-longevity link. The integrating brief acknowledges that null findings dominate the cardiometabolic class and that mechanistically plausible cardiometabolic targets coexist with sparse human RCT confirmation. By contrast, the SOLID diabetes-stratified design in Lacy 2022 highlights where subgroup-specific cognitive vulnerability could recalibrate a downstream null; future work pairing SOLID-style stratification with inflammaging biomarkers à la Villaplana-Velasco 2025 would directly address the boundary conditions the current corpus leaves unresolved. [bundle:22] [bundle:24] [bundle:26] [bundle:33]

### Contextual Adjacent Evidence Outcomes


This outcome class aggregates the heterogeneous ancillary evidence surrounding longevity subgroups, spanning clinical RCTs, observational cohorts, mechanistic human studies, and preclinical models. The remaining sources are indirect observational cohorts and reviews; Lu 2024 dissects physical vs sedentary behaviors on longevity and age acceleration using linear and Poisson regression, Joshi 2025 is a systematic review and meta-analysis of lifestyle interventions in adults aged 50 years or more, and Aliberti 2025 reviews exposome drivers of healthy aging across Blue Zones and Cilento. [bundle:4] [bundle:11] [bundle:37]

Mechanistically, the substrate underlying this class is multilayered. Preclinical data from Chevret 2026 point to tissue-specific mitochondrial pathway remodeling in long-lived honeybee queens as a candidate axis for lifespan divergence, with statistical separation concentrated on queen-vs-worker contrasts. Human observational evidence from Lu 2024 implicates physical-activity intensity gradients (P < 0.001, P < 0.05, P < 0.01) and Kubo 2025 corroborates the MVPA-sedentary behavior dichotomy in community-dwelling older adults, while the clinical RCTs of Ramos 2026 and Ribeiro 2025 interrogate restoration- and hypersensitivity-level analogues of tissue durability rather than systemic aging endpoints. [bundle:4] [bundle:10] [bundle:19] [bundle:30] [bundle:36]

Within-corpus tensions in this outcome class stem chiefly from a directness asymmetry: the direct human RCT sources (Ribeiro 2025; Ramos 2026) interrogate narrow dental-restoration and dentin-hypersensitivity endpoints, whereas the indirect observational and review sources (Lu 2024, Joshi 2025, Gomez 2024, Aliberti 2025, Khalil 2025, Reddy 2025, Zhu 2025, Kubo 2025, Chevret 2026, Hoshi 2026, Yuan 2026, Abdelraheem 2026, Horton 2026, Luo 2026, Chen 2022) span behavior, genetics, environment, and preclinical models. By contrast, Joshi 2025 and Aliberti 2025 frame lifestyle and exposome inputs at population scale, while Gomez 2024 reports sharply elevated restoration-failure hazards in a defined clinical subgroup, illustrating how subgroup-level effect sizes can diverge from population-level synthesis. The trial was designed to support analyses of aging-relevant phenotypes in a population where frailty and pre-frailty are prevalent, making it the principal direct evidence source for this outcome class. Endpoint construction and randomization details are summarized in the evidence synthesis. [bundle:4] [bundle:10] [bundle:11] [bundle:14] [bundle:15] [bundle:16] [bundle:17] [bundle:19] [bundle:20] [bundle:23] [bundle:27] [bundle:28] [bundle:30] [bundle:32] [bundle:35] [bundle:36] [bundle:37]

### Immune and Inflammation Outcomes


Two sources anchor the immune and inflammatory outcome class for the Longevity synthesis. Adibi 2026 is a review and proposed digital-health framework paper that integrates microbiome and lifestyle data around an inflammation-centered model, citing Blue Zone and Mediterranean diet evidence as upstream inputs to the platform concept (Adibi 2026). Together these two sources form the entire immune-class evidence available in the corpus, and they differ fundamentally in design: one is a primary cohort analysis, the other a conceptual synthesis paper. [bundle:3]

Quantitative findings in this outcome class are limited and unevenly reported. Adibi 2026 reports a single quantitative anchor of P < 0.001 for an inflammation-related analytic claim within the framework paper (Adibi 2026). Per the synthesis brief, the dominant quantitative signal for the immune class sits with Adibi 2026 (P < 0.001), while Chen 2019 contributes cohort scale rather than a test statistic. [bundle:3] [bundle:38]

Mechanistically, the immune class evidence maps onto a single shared substrate — systemic inflammation as a longevity modulator — through two complementary lenses. Chen 2019 frames this as the joint prognostic signal of hs-CRP, an established acute-phase inflammatory biomarker (Studenski 2011 is the canonical reference for frailty biomarker selection), and cognitive function on all-cause mortality in adults at advanced ages (Chen 2019). Adibi 2026 frames the same substrate from a digital-health and lifestyle vantage, treating inflammation as a tractable endpoint that connects microbiome composition and dietary patterns to downstream aging trajectories (Adibi 2026). The convergence is that inflammation is treated as both a prognostic marker (Chen 2019) and a modifiable target (Adibi 2026), even though neither source establishes causation directly. [bundle:3] [bundle:38]

Within-corpus tensions in this outcome class are methodological rather than directional. The Chen 2019 cohort provides directness to oldest-old mortality risk but yields an unclear effect direction with no reported p-value, while the Adibi 2026 framework paper produces a statistically supported inflammation signal (P < 0.001) but is mechanistic and indirect in population terms (Chen 2019; Adibi 2026). The disagreement is therefore one of evidence weight: a primary observational cohort with ambiguous direction versus a conceptual synthesis with a stronger reported numeric but weaker population directness. This is consistent with the broader brief-level observation that mechanistic plausibility in the Longevity case coexists with mixed or sparse human evidence and that boundary conditions remain to be established. [bundle:3] [bundle:38]

Within the curated corpus, Qiu 2025 (observational cohort; indirect for the longevity endpoint) is the sole source mapped to the immune inflammation class for the Longevity topic. The study combines observational analyses with summary-data-based Mendelian randomization (SMR/GSMR) in adults, reporting a panel of P-values spanning immune and aging-related phenotypes (P = 0.015, P = 0.312, P = 0.255, P < 0.001, P = 0.0385, P = 0.0003, P = 0.023, P > 0.05, P = 0.055, P = 0.077, P < 0.05). These numerics trace the full breadth of the cohort's secondary outcomes rather than a single primary effect, and the source itself flags effect direction as unclear, which constrains interpretation of any one P-value in isolation. [bundle:12]

the inference to immune inflammation as a class is a triangulation: severe infection is used as a proxy for the inflammatory-exposure construct, and longevity is the downstream phenotypic readout. The substrate therefore consists of human observational and human genetic-instrument data, with no mechanistic-human substudy and no preclinical arm represented in this outcome class within the curated corpus.

The mixed secondary P-value pattern (some P < 0.05, several P > 0.05) means the immune inflammation evidence is best characterized as a single-source signal with internal heterogeneity, rather than a converging multi-source finding. This boundary condition is consistent with the brief's framing that mechanistic plausibility coexists with mixed or sparse human evidence.

Evidence for this outcome class is represented in the structured results table, but the retained narrative paragraphs were more strongly assigned to adjacent outcome classes. The synthesis therefore treats this class as context for cross-domain interpretation rather than as a standalone prose claim.

### Longevity Outcomes


Eight observational cohorts and two evidence syntheses form the longevity evidence base, all classified as indirect with respect to the central question and predominantly enrolling community-dwelling adults aged 50 years and older. The Chinese Longitudinal Healthy Longevity Survey (CLHLS) anchors the corpus through three independent analyses: Wang 2024a followed frail/sarcopenic participants across waves 2011–2014, Chen 2026b examined healthy lifestyle and multimorbidity networks, and Chen 2026a stratified oldest-old participants by a modifiable risk factor score (MRFS) [Wang 2024a; Chen 2026b; Chen 2026a]. [bundle:2] [bundle:7] [bundle:18]

Quantitatively, favorable risk profiles were associated with substantial mortality reductions across multiple cohorts. Chen 2026b identified a favorable lifestyle as protective against all-cause mortality (P < 0.001) [Chen 2026b]. the evidence synthesis catalogs each study × p-value tuple so that effect-direction heterogeneity across the eight cohorts can be inspected at a glance. [bundle:18]

Additional corpus sources included animal/preclinical evidence; mechanistically, the convergence of favorable lifestyle, low cardiometabolic burden, and preserved physical function onto a common mortality-reduction pathway is biologically coherent. Preclinical and translational data in Barinda 2024 provide mechanistic plausibility for pharmacological repurposing, noting that acetazolamide increased lifespan by nearly 201% in kl/kl mice, although clinical translation to human longevity endpoints remains nascent [Barinda 2024]. Ajnakina 2023 layers polygenic longevity propensity and APOE-ε4 onto these mechanism-oriented observational contrasts, linking genotype, dementia diagnosis, and cause-specific mortality within the same English cohort [Ajnakina 2023]. [bundle:5] [bundle:25]

Within-corpus tensions are most visible in the heterogeneity of effect direction across observational cohorts, and the disagreement is best read through study-level contrasts rather than through any single integrative statistic. Yokokawa 2023, Dai 2023, and Huang 2026 likewise carry mixed or unclear directionality even where point estimates and p-values are conventionally strong, suggesting that the longevity/lifespan signal is not uniformly directional across exposure definitions, subpopulations, or cause-specific endpoints [Yokokawa 2023; Dai 2023; Huang 2026]. This dispersion — favorable MRFS, LE8, lifestyle, and frailty transitions all showing conventional significance but no source achieving unanimous directional coding — is the principal internal tension the synthesis surfaces for this outcome class. [bundle:8] [bundle:13] [bundle:21]

### Mortality and Survival Outcomes


Two observational cohort studies in the curated corpus address all-cause mortality and survival beyond age 90 in adult populations, each with extended follow-up and large sampling frames. Liu 2025 used the Chinese Longitudinal Healthy Longevity Survey (CLHLS) to evaluate how sources of income relate to all-cause mortality in older adults, reporting statistically significant associations across multiple income-source contrasts (Liu 2025). Deelen 2014 conducted a genome-wide association meta-analysis of human longevity, identifying loci conferring survival beyond 90 years of age and estimating the genetic contribution to lifespan variation at approximately one-quarter (Deelen 2014). Detailed endpoint-by-endpoint p-values for both studies are tabulated in the evidence synthesis (Per-Study Endpoint Evidence). [bundle:1] [bundle:39]

Quantitatively, Liu 2025 reported that, compared with the main income from family support, other types of income were associated with a reduced mortality risk, with between-group significance reaching P = 0.015, P < 0.001, and P = 0.031 across the reported income-source contrasts (Liu 2025). [bundle:1]

Mechanistically, the two studies occupy different but complementary levels of explanation. Deelen 2014 frames longevity as a heritable trait with identifiable genetic contributors, locating the mechanistic substrate in host-genome variation that influences survival past the ninth decade (Deelen 2014). Liu 2025, by contrast, frames mortality risk in later life as socially embedded, with income source — a downstream proxy for material and social resources — modifying hazard, consistent with the social-determinants pathway implicated in older-adult mortality literature (Liu 2025). Both pathways converge on the same outcome class but operate at distinct levels: genomic predisposition versus socioeconomic exposure. [bundle:1] [bundle:39]

Within the curated corpus on mortality and survival, the two contributing studies do not disagree on direction but differ in scope and directness. Liu 2025 is an indirect observational cohort in which the exposure of interest is income source rather than a biological intervention, so its applicability to intervention-based longevity questions is bounded (Liu 2025). Cases were selected for familial longevity and compared against age-matched controls, with frailty and sarcopenia status ascertained through standardized phenotypic assessments. Because the design is observational and the longevity phenotype is defined by family history rather than a randomized intervention, the directness of inference to a longevity-subgroup intervention effect is rated as indirect in the curated evidence base. [bundle:1]

These values are reproduced verbatim in the evidence synthesis (Per-Study Endpoint Evidence), which carries every study × p-value tuple so that the prose can reference rather than restate the full numeric matrix. The source does not provide a clear single direction of effect (effect direction: unclear), and no hazard ratio, odds ratio, or effect-size point estimate is supplied in the source text. Consequently, quantitative interpretation here is restricted to the discrete set of p-values enumerated above, and no composite score or pooled estimate is derivable from a single observational cohort.

### Skeletal, Fracture, and Bone Outcomes


The Healthy Longevity and Ageing in Place (HOPE) randomized controlled trial evaluated multicomponent integrated care (MIC) versus usual care (UC) among rural community-dwelling older adults, with endpoints spanning intrinsic capacity, happiness, and skeletal health biomarkers over the protocol-specified follow-up window [Chang 2025]. The trial enrolled older adults as the primary population and was designed as a human RCT with mechanistic/biomarker endpoints. The direction of effect for the skeletal fracture and bone health class was unclear in the source extract, which is consistent with the relatively weaker and non-significant tail of the reported p-value distribution. The two most robust contrasts (P = 0.01 and P = 0.003) and the marginal signals (P = 0.05, P = 0.04) do not align cleanly with skeletal endpoints in the available excerpt, while P = 0.28 lies within the conventional null range. [bundle:29]

Mechanistically, bone-health endpoints in older adults are linked to the same sarcopenic, inflammatory, and reduced-mobility substrates that drive intrinsic-capacity decline, so a multicomponent integrated care intervention plausibly engages shared pathways even where the fracture-specific contrast does not achieve conventional significance [Chang 2025]. In a clinical RCT design of this kind, biomarker readouts in bone turnover and functional mobility are expected to move together with broader capacity metrics when the intervention exerts a genuine systemic effect. The source-level unclear direction for the skeletal class should therefore be read as a function-specific absence rather than a global null result. [bundle:29]

The Chang 2025 HOPE trial is the sole curated entry within the skeletal fracture and bone outcome class, so within-corpus tensions across studies cannot be resolved from the present corpus and no disagreements by author name are surfaced in this subsection. The reader is referred to the evidence synthesis (Per-Study Endpoint Evidence) for the complete per-study p-value mapping, where every Chang 2025 endpoint is recorded with its exact contrast and statistical result. Until additional curated skeletal RCTs are added, the bone-health subquestion must be characterized as a single-trial, mixed-signal evidence base requiring further replication. [bundle:29]

### Frailty Outcomes


Quantitative findings on frailty from Wang 2024b are reported as null in the supplied excerpt, with no p-values or effect-direction markers attached to frailty endpoints in the source payload. These numerics contextualize the trial's population rather than serving as efficacy read-outs; they signal that the disease burden the nucleotide intervention is positioned against is itself heterogeneous. No trial-level efficacy estimate can be transcribed from Wang 2024b without exceeding the source evidence. [bundle:31]

Mechanistically, the frailty outcome class in this corpus is supported by one clinical RCT (Wang 2024b) measuring functional endpoints directly, paired with one observational cohort (Chen 2024) characterizing sarcopenia prevalence at the population level. Chen 2024 frames sarcopenia as a target for precision-health interventions aimed at healthy longevity, providing a mechanistic rationale for why a nucleotide-based intervention could plausibly act on frailty-relevant endpoints. Together the two sources link a population-level disease-burden argument to a within-trial functional-endpoint design, although the trial itself has not yet yielded a published efficacy estimate in the supplied material. [bundle:31] [bundle:34]

Within-corpus tension on frailty centers on the directness gap flagged between Wang 2024b and Chen 2024: Wang 2024b is a direct trial of frailty-relevant endpoints in older adults, whereas Chen 2024 is an indirect, observational prevalence synthesis that does not test the intervention. The two sources therefore should not be read as competing estimates of intervention efficacy; instead, Chen 2024 supplies the population-level denominator against which Wang 2024b's functional-endpoint results, when reported, will be calibrated. This direct-versus-indirect separation is the principal interpretive constraint on the frailty outcome class in the present corpus. [bundle:31] [bundle:34]

Frailty remains a separate Results slice for Longevity Lifespan Subgroups (n=2; claims=15; no extracted directional signal in 2/2 sources; 1 direct; 1 indirect; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. The source's framing positions frailty and sarcopenia as phenotypic correlates of longevity rather than as primary endpoints of an intervention, and the indirect directness rating reflects this surrogate-phenotype interpretation. Preclinical data on conserved longevity pathways and clinical observations of preserved appendicular lean mass in offspring of nonagenarian siblings are consistent with the mechanistic substrate, but no such preclinical or mechanistic human-study sources are present in the curated corpus for the Longevity topic.

Direction reconciliation: source-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction.

### Muscle Function Outcomes


Within-corpus tensions for the muscle function outcome class cannot be enumerated from non-orthogonal pairings because the cross-study disagreement map contains no same-outcome non-orthogonal pairs for muscle function. The principal limitation is therefore one of evidence density: a single observational cohort (Belenguer-Varea 2023) anchors the outcome class, and no clinical RCT, mechanistic human study, or preclinical source is available to triangulate the observation. The clear-direction-of-effect ambiguity (effect direction: unclear) further constrains interpretation, and additional longitudinal cohorts with harmonized sarcopenia and frailty endpoints would be required to resolve the directional question raised by the Belenguer-Varea 2023 contrasts. [bundle:6]

Muscle Function remains a separate Results slice for Longevity Lifespan Subgroups (n=1; claims=59; significant source statistic in 1/1 sources; source-level direction coded unclear; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Belenguer-Varea 2023 (Effect of Familial Longevity on Frailty and Sarcopenia: A Case–Control Study; representative statistic P = 0.001; source-level statistic reported; outcome=Muscle Function; direction=unclear; directness=indirect; tier=B2). [bundle:6]

## Cross-Domain Synthesis

The most consequential cross-outcome tension in this corpus pits direct human clinical evidence in frailty and skeletal endpoints against indirect observational signals on longevity itself. Wang 2024b is an RCT targeting aging biomarkers via exogenous nucleotides in community-dwelling adults aged 60–70, while Chang 2025 is an RCT (the HOPE trial) reporting that multicomponent integrated care significantly affected intrinsic capacity outcomes in rural community-dwelling older adults, with effect-direction annotated as mixed. Both are direct, but neither was designed or powered to detect a hard mortality endpoint. The mechanistic reading is that biomarker or intrinsic-capacity gains in 60–80-year-olds plausibly feed forward into late-life survival, but the boundary condition matters enormously: the RCTs enrol narrow age strata and short follow-up, whereas the cohort longevity signals emerge over decades. The two classes of evidence are not in direct contradiction; they are speaking at different temporal resolutions. Resolving this tension requires either an adequately powered pragmatic RCT with mortality endpoints or pooled individual-participant meta-analyses of cohort longevity subgroups harmonized onto comparable modifiable-risk-factor exposures. [bundle:29] [bundle:31]

Additional corpus sources included animal/preclinical evidence; a second signature tension runs between the animal/preclinical longevity literature and the human cardiometabolic and immune-inflammation evidence. Barinda 2024 (systematic review of repurposed cardiovascular-metabolic drugs) reports near 201% lifespan extension in kl/kl mice after acetazolamide treatment, and Chevret 2026 documents tissue-specific mitochondrial pathway remodeling in honeybee queens that often live more than two years. The mechanism-level reading is that mitochondrial and inflammaging pathways are evolutionarily conserved enough that model-organism results are biologically credible, yet the boundary condition is that translation to human survival remains unproven; human RCTs of the same pathways act on cardiometabolic intermediates, not longevity. The evidence that would resolve this is a long-horizon human RCT using validated cardiometabolic drugs against hard mortality endpoints in well-characterized subgroups — and until then, model-organism lifespan extension must be presented as hypothesis-generating, not as evidence for human longevity gains. [bundle:10] [bundle:25]

Another tension, located inside the frailty outcome class itself, concerns directness rather than direction. Wang 2024b is the lone direct RCT for frailty in this corpus, and its design targets exogenous nucleotide effects on aging biomarkers. The mechanical discrepancy is straightforward: direct RCTs measure intervention efficacy under controlled exposure, whereas indirect cohorts measure association under self-selected exposure, and the canonical gait-speed framework — Studenski 2011's 0.8 m/s threshold and Cesari 2009's 0.6 m/s severe-frailty cutoff — operationalizes frailty in the indirect literature but cannot be assumed to map onto RCT enrolment criteria. What would resolve the tension is harmonization of frailty operationalization (Cruz-Jentoft 2019's 27 kg / 16 kg grip-strength cutoffs for men and women, respectively) across both RCT entry criteria and cohort definitions, so that direct and indirect evidence can be pooled without category error. [bundle:31]

Another tension sits at the boundary between surrogate biomarkers and hard outcomes, and it is the methodological fault line that recurs across the dossier. 

A fifth and final tension, specific to this corpus, concerns the divergence between two ostensibly positive survival signals and a negative longevity signal that the integrating thesis flags. Against these positive mortality/survival signals, Chen 2026b is annotated as effect-direction negative on longevity, with a healthy lifestyle associated with lower all-cause mortality risk in CLHLS (P < 0.001). The mechanical reading is that income source, genetic background, and lifestyle each predict survival in cohorts, but lifestyle is reported with an explicitly negative direction in one major subgroup analysis, while income and genetics are reported with positive or mixed directions elsewhere. The boundary condition is geography and cohort: Liu 2025, Chen 2026a, Chen 2026b, Wang 2024a, and Gao 2024 all draw on CLHLS, so the negative-direction lifestyle signal in Chen 2026b is not a refutation of the positive mortality signals in Liu 2025 and Deelen 2014 — it is a statement about which subgroups within CLHLS exhibit lifestyle-attributable longevity gradients. Resolving this tension requires reporting absolute effect sizes and subgroup definitions side-by-side; conflating them, as some of the indirectness-gap and mechanism-vs-clinical pairs above invite, will systematically obscure where the Longevity literature actually stands. [bundle:1] [bundle:2] [bundle:7] [bundle:9] [bundle:18] [bundle:39]

### Boundary-condition synthesis

Interpreting the cross-domain evidence requires treating each domain as
part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings
explain plausible pathways; indirect findings identify where transfer
across populations, time horizons, or measurement systems remains
uncertain. This separation is important because evidence can be valid
within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical
findings when making patient-facing claims, uses mechanistic evidence
to explain why effects might diverge, and treats discordance as a
signal about applicability rather than as a reason to average unlike
endpoints together.

We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.
## Discussion

**Thesis:** Across 40 curated reference papers, the evidence base for Longevity shows a context-dependent profile. Positive signals appear in: mortality survival. Negative signals appear in: longevity. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Longevity broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 40 included sources. The evidence-tier distribution is: B2 (n=34), A1 (n=4), B1 (n=2). The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 3 distinct summaries across the source set: frail / sarcopenic adults; older adults; adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The absence of any long-term mortality RCT in this corpus is itself a structural limit on inference.

Several longevity-relevant outcomes are documented by only a single source, which means that within-corpus replication is impossible. Because each of these outcomes is touched by one source, any precision statistic or sensitivity claim is structurally unreplicable inside the corpus.

Population specificity narrows the external validity of the synthesis. 

The endpoint scope is narrow. Hard clinical endpoints such as incident frailty, hospitalization, or cause-specific cardiovascular death are reported only as secondary or tertiary outcomes (e. For example, Wang 2024a, Gao 2024), limiting the strength of any inference about functional aging trajectories. [bundle:2] [bundle:9]

Additional corpus sources included animal/preclinical evidence; the mechanism-to-clinic gap is wide. Surrogate biomarkers in this corpus are not backed by mortality-RCT confirmation, which is consistent with the general caution that surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005). The Chang 2025 RCT reports intrinsic-capacity and happiness outcomes rather than survival, the Wang 2024b TALENTs nucleotide RCT is a baseline/design paper with no clinical endpoint yet, and the Barinda 2024 systematic review notes that even a near-201% lifespan extension in kl/kl mice has not translated clinically, all of which means the mechanistic plausibility for any clinically-relevant longevity claim in this corpus remains unverified by within-corpus randomized data. Translational relevance to humans remains uncertain. [bundle:25] [bundle:29] [bundle:31]

### Residual uncertainty

The main limitation is not only the size of the retained corpus, but
also the uneven directness of the evidence across outcome classes. Some findings are clinically proximate, some are mechanistic, and some
are indirect or model-system evidence. The paper therefore avoids
treating all sources as equivalent. Its conclusions are strongest
where directness, clinical directness, and source-context safety align,
and weaker where evidence must be translated across populations,
species, intervention schedules, or measurement systems.

## Conclusion

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.

### Bounded conclusion

This synthesis supports a bounded interpretation across 40 included sources. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

A defensible next study should pre-specify
which endpoint layer it intends to test, align intervention exposure with
that endpoint, and report functional or safety tradeoffs with the same
visibility as benefit signals. Agreement across mechanistic, intermediate,
functional, and hard-clinical layers would support stronger inference than
any isolated signal; disagreement across those layers should be treated as
a design problem rather than averaged into a single geroprotective claim.

## What This Synthesis Adds

This synthesis maps 40 included sources on Longevity Lifespan Subgroups across 9 outcome classes and 144 cross-study disagreements. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

The strongest unresolved contrast is the mechanism vs clinical between Dai 2023 and Wang 2024b on longevity (severity 3/5), which defines the boundary condition future studies must test rather than smooth over. [bundle:13] [bundle:31]

Additional corpus sources included animal/preclinical evidence; prior reviews in the corpus (Joshi 2017, Barinda 2024) emphasize convergent signals on Longevity Lifespan Subgroups. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary. [bundle:25] [bundle:40]

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| longevity | 0 | 10 | mixed, negative, unclear | direct interventional hard-endpoint gap |
| cardiometabolic | 0 | 4 | null, unclear | direct interventional hard-endpoint gap |
| immune and inflammation | 0 | 2 | unclear | direct interventional hard-endpoint gap |
| muscle function | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| frailty | 1 | 1 | null | replication gap |
| immune and inflammation | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| mortality and survival | 0 | 2 | positive, unclear | direct interventional hard-endpoint gap |
| contextual adjacent evidence | 2 | 15 | null, unclear | replication gap |
| skeletal, fracture, and bone | 1 | 0 | unclear | replication gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 10 indirect sources; direction profile: mixed, negative, unclear |
| P2 | cardiometabolic: direct interventional hard-endpoint gap | 0 direct and 4 indirect sources; direction profile: null, unclear |
| P3 | immune and inflammation: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: unclear |
| P4 | muscle function: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |
| P5 | frailty: replication gap | 1 direct and 1 indirect sources; direction profile: null |

### Next-Study Design Recommendation

The next high-yield study for Longevity Lifespan Subgroups should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence; Ramos 2026; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null; representative statistic=P > 0.05. [bundle:19]
- Chang 2025; tier=A1; directness=direct; endpoint=skeletal fracture bone; direction=unclear; representative statistic=P = 0.003. [bundle:29]
- Wang 2024b; tier=A1; directness=direct; endpoint=frailty; direction=null. [bundle:31]
- Ribeiro 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null. [bundle:36]
- Joshi 2017; tier=B1; directness=review; endpoint=longevity; direction=unclear. [bundle:40]
- Barinda 2024; tier=B1; directness=review; endpoint=longevity; direction=unclear. [bundle:25]
- Liu 2025; tier=B2; directness=indirect; endpoint=mortality survival; direction=unclear; representative statistic=P < 0.001. [bundle:1]
- Wang 2024a; tier=B2; directness=indirect; endpoint=longevity; direction=mixed; representative statistic=P < 0.001. [bundle:2]
- Chen 2019; tier=B2; directness=indirect; endpoint=immune; direction=unclear. [bundle:38]
- Adibi 2026; tier=B2; directness=indirect; endpoint=immune; direction=unclear; representative statistic=P < 0.001. [bundle:3]

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 3 indirectness gap: Gomez 2024 vs Ribeiro 2025; Ribeiro 2025 (direct, A1) vs Gomez 2024 (indirect) on contextual other — direct vs indirect must be kept separate [bundle:17] [bundle:36]
- Severity 3 indirectness gap: Gomez 2024 vs Ramos 2026; Ramos 2026 (direct, A1) vs Gomez 2024 (indirect) on contextual other — direct vs indirect must be kept separate [bundle:17] [bundle:19]
- Severity 3 indirectness gap: Wang 2024b vs Chen 2024; Wang 2024b (direct, A1) vs Chen 2024 (indirect) on frailty — direct vs indirect must be kept separate [bundle:31] [bundle:34]
- Severity 3 indirectness gap: Aliberti 2025 vs Ribeiro 2025; Ribeiro 2025 (direct, A1) vs Aliberti 2025 (indirect) on contextual other — direct vs indirect must be kept separate [bundle:36] [bundle:37]
- Severity 3 indirectness gap: Aliberti 2025 vs Ramos 2026; Ramos 2026 (direct, A1) vs Aliberti 2025 (indirect) on contextual other — direct vs indirect must be kept separate [bundle:19] [bundle:37]
- Severity 3 indirectness gap: Khalil 2025 vs Ribeiro 2025; Ribeiro 2025 (direct, A1) vs Khalil 2025 (review) on contextual other — direct vs indirect must be kept separate [bundle:28] [bundle:36]
- Severity 3 indirectness gap: Khalil 2025 vs Ramos 2026; Ramos 2026 (direct, A1) vs Khalil 2025 (review) on contextual other — direct vs indirect must be kept separate [bundle:19] [bundle:28]
- Severity 3 indirectness gap: Reddy 2025 vs Ribeiro 2025; Ribeiro 2025 (direct, A1) vs Reddy 2025 (indirect) on contextual other — direct vs indirect must be kept separate [bundle:14] [bundle:36]




## References

- **Liu 2025.** _Sources of income are associated with all-cause mortality risk in older people: results from the Chinese longitudinal healthy longevity survey (CLHLS)._ BMC Public Health, 2025. DOI: 10.1186/s12889-025-25435-9 PMID: 41299359.
- **Wang 2024a.** _Association of changes in frailty status with the risk of all-cause mortality and cardiovascular death in older people: results from the Chinese Longitudinal Healthy Longevity Survey (CLHLS)._ BMC Geriatrics, 2024. DOI: 10.1186/s12877-024-04682-2 PMID: 38267867.
- **Chen 2019.** _Combined associations of hs-CRP and cognitive function with all-cause mortality among oldest-old adults in Chinese longevity areas: a prospective cohort study._ Immunity & Ageing : I & A, 2019. DOI: 10.1186/s12979-019-0170-y PMID: 31832073.
- **Adibi 2026.** _A Conceptual Digital Health Framework for Longevity Optimization: Inflammation-Centered Approach Integrating Microbiome and Lifestyle Data—A Review and Proposed Platform._ Nutrients, 2026. DOI: 10.3390/nu18020231 PMID: 41599842.
- **Lu 2024.** _Active longevity and aging: dissecting the impacts of physical and sedentary behaviors on longevity and age acceleration._ GeroScience, 2024. DOI: 10.1007/s11357-024-01329-3 PMID: 39230773.
- **Ajnakina 2023.** _Polygenic Propensity for Longevity, APOE -ε4 Status, Dementia Diagnosis, and Risk for Cause-Specific Mortality: A Large Population-Based Longitudinal Study of Older Adults._ The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2023. DOI: 10.1093/gerona/glad168 PMID: 37434484.
- **Belenguer-Varea 2023.** _Effect of Familial Longevity on Frailty and Sarcopenia: A Case–Control Study._ International Journal of Environmental Research and Public Health, 2023. DOI: 10.3390/ijerph20021534 PMID: 36674289.
- **Chen 2026a.** _Modifiable risk factors attenuated longevity genetic predisposition on life expectancy in the oldest old._ NPJ Aging, 2026. DOI: 10.1038/s41514-026-00393-7 PMID: 42086614.
- **Yokokawa 2023.** _How Long Would You Like to Live? A 25-year Prospective Observation of the Association Between Desired Longevity and Mortality._ Journal of Epidemiology, 2023. DOI: 10.2188/jea.JE20210493 PMID: 35527000.
- **Gao 2024.** _Association of frailty with cardiovascular and all-cause mortality in community-dwelling older adults: insights from the Chinese longitudinal healthy longevity survey._ Frontiers in Cardiovascular Medicine, 2024. DOI: 10.3389/fcvm.2024.1499099 PMID: 39764284.
- **Joshi 2025.** _Evidence-Based Pathways to Healthy Aging: A Systematic Review and Meta-analysis of Lifestyle Interventions for Longevity and Well-Being._ Investigacion y Educacion en Enfermeria, 2025. DOI: 10.17533/udea.iee.v43n3e06 PMID: 41289530.
- **Chevret 2026.** _Tissue-specific mitochondrial pathway remodeling linked to longevity in honeybee queens._ PLOS One, 2026. DOI: 10.1371/journal.pone.0341233 PMID: 41604424.
- **Qiu 2025.** _COVID-19 infection and longevity: an observational and mendelian randomization study._ Journal of Translational Medicine, 2025. DOI: 10.1186/s12967-024-05932-y PMID: 40050903.
- **Dai 2023.** _Combined associations of vitamin D and cognitive function with all-cause mortality among older adults in Chinese longevity areas: A prospective cohort study._ Frontiers in Public Health, 2023. DOI: 10.3389/fpubh.2023.1024341 PMID: 37206876.
- **Deelen 2014.** _Genome-wide association meta-analysis of human longevity identifies a novel locus conferring survival beyond 90 years of age._ Human Molecular Genetics, 2014. DOI: 10.1093/hmg/ddu139 PMID: 24688116.
- **Reddy 2025.** _Battery longevity of a helix-fixation dual-chamber leadless pacemaker: results from the AVEIR DR i2i Study._ Europace, 2025. DOI: 10.1093/europace/euaf074 PMID: 40474610.
- **Zhu 2025.** _Relationship between Sn elemental background values and regional longevity levels—Data from Yunnan, China._ PLOS One, 2025. DOI: 10.1371/journal.pone.0332369 PMID: 40938926.
- **Yuan 2026.** _A Weibull distribution-based method for estimating seed longevity in Solanum rostratum._ Frontiers in Plant Science, 2026. DOI: 10.3389/fpls.2026.1700839 PMID: 41835274.
- **Gomez 2024.** _Longevity of dental restorations in Sjogren’s disease patients using electronic dental and health record data._ BMC Oral Health, 2024. DOI: 10.1186/s12903-024-03957-9 PMID: 38326771.
- **Chen 2026b.** _Healthy Lifestyle, multimorbidity network, and all-cause mortality among older Chinese: a longitudinal analysis in Chinese longitudinal healthy longevity survey._ BMC Public Health, 2026. DOI: 10.1186/s12889-026-26294-8 PMID: 41540410.
- **Ramos 2026.** _Longevity of different in-office treatments for dentin hypersensitivity: A 6-month randomized and parallel clinical trial._ PLOS One, 2026. DOI: 10.1371/journal.pone.0342651 PMID: 41701705.
- **Luo 2026.** _The effect of arteriovenous fistula longevity preservation exercise program combined with video-assisted patient education on fistula maturation for maintenance hemodialysis patients._ Frontiers in Medicine, 2026. DOI: 10.3389/fmed.2026.1788809 PMID: 42245946.
- **Huang 2026.** _Life’s Essential 8 and healthy longevity among people with and without cardiometabolic multimorbidity: A prospective study of UK Biobank._ American Journal of Preventive Cardiology, 2026. DOI: 10.1016/j.ajpc.2026.101433 PMID: 41624045.
- **Joshi 2017.** _Genome-wide meta-analysis associates HLA-DQA1/DRB1 and LPA and lifestyle factors with human longevity._ Nature Communications, 2017. DOI: 10.1038/s41467-017-00934-5 PMID: 29030599.
- **Lacy 2022.** _Comparison of cognitive function in older adults with type 1 diabetes, type 2 diabetes, and no diabetes: results from the Study of Longevity in Diabetes (SOLID)._ BMJ Open Diabetes Research & Care, 2022. DOI: 10.1136/bmjdrc-2021-002557 PMID: 35346969.
- **Horton 2026.** _Relationship between antibody avidity, Fc-mediated functional activity and longevity of malaria vaccine responses in clinical trials._ Frontiers in Immunology, 2026. DOI: 10.3389/fimmu.2026.1808822 PMID: 42023224.
- **Barinda 2024.** _Repurposing effect of cardiovascular-metabolic drug to increase lifespan: a systematic review of animal studies and current clinical trial progress._ Frontiers in Pharmacology, 2024. DOI: 10.3389/fphar.2024.1373458 PMID: 38966557.
- **Martini 2026.** _Early Biomarkers, Risk Factors, and Functional Indicators of Healthy Longevity and Their Relationship with Diet._ Nutrients, 2026. DOI: 10.3390/nu18111664 PMID: 42280310.
- **Villaplana-Velasco 2025.** _Mendelian randomization study implicates inflammaging biomarkers in retinal vasculature, cardiovascular diseases, and longevity._ Science Advances, 2025. DOI: 10.1126/sciadv.adu1985 PMID: 41134885.
- **Khalil 2025.** _Green Environments for Sustainable Brains: Parameters Shaping Adaptive Neuroplasticity and Lifespan Neurosustainability—A Systematic Review and Future Directions._ International Journal of Environmental Research and Public Health, 2025. DOI: 10.3390/ijerph22050690 PMID: 40427807.
- **Hoshi 2026.** _Structural Relationships of Socioeconomic Factors Influencing Diet, Lifestyle Habits, Having a Dentist, and Health Factors That Impact Healthy Life Longevity for the Elderly._ Nutrients, 2026. DOI: 10.3390/nu18030382 PMID: 41683206.
- **Chang 2025.** _Effects of osteoporosis treatment and multicomponent integrated care on intrinsic capacity and happiness among rural community-dwelling older adults: the Healthy Longevity and Ageing in Place (HOPE) randomised controlled trial._ Age and Ageing, 2025. DOI: 10.1093/ageing/afaf017 PMID: 39907488.
- **Kubo 2025.** _Physical activity associations with physical function and body composition among community‐dwelling older adults in Japan: The Kyotango Longevity Cohort Study._ Geriatrics & Gerontology International, 2025. DOI: 10.1111/ggi.70189 PMID: 41024459.
- **Wang 2024b.** _Targeting Aging and Longevity with Exogenous Nucleotides (TALENTs): Rationale, Design, and Baseline Characteristics from a Randomized Controlled Trial in Older Adults._ Nutrients, 2024. DOI: 10.3390/nu16091343 PMID: 38732590.
- **Chen 2022.** _TOMM40 genetic variants associated with healthy aging and longevity: a systematic review._ BMC Geriatrics, 2022. DOI: 10.1186/s12877-022-03337-4 PMID: 35964003.
- **Wu 2026.** _Time-restricted eating as a potential strategy for healthy lifespan: an evaluation of current evidence._ Frontiers in Medicine, 2026. DOI: 10.3389/fmed.2025.1701888 PMID: 41601725.
- **Chen 2024.** _Sarcopenia in the era of precision health: Toward personalized interventions for healthy longevity._ Journal of the Chinese Medical Association : JCMA, 2024. DOI: 10.1097/JCMA.0000000000001164 PMID: 39257038.
- **Abdelraheem 2026.** _Genetic, Socioecological, and Health Research on Extreme Longevity in Semisupercentenarians and Supercentenarians: A Scoping Review._ Journal of Aging Research, 2026. DOI: 10.1155/jare/1605361 PMID: 42007363.
- **Ribeiro 2025.** _Assessment of photobiomodulation combined with new restorative material for teeth with molar incisor hypomineralization on control of hypersensitivity and longevity of restorations: Protocol for a randomized controlled blind clinical trial._ PLOS One, 2025. DOI: 10.1371/journal.pone.0329641 PMID: 40802785.
- **Aliberti 2025.** _The Power of Environment: A Comprehensive Review of the Exposome’s Role in Healthy Aging, Longevity, and Preventive Medicine—Lessons from Blue Zones and Cilento._ Nutrients, 2025. DOI: 10.3390/nu17040722 PMID: 40005049.

{
  "article_type": "research_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "eb8eeda4-bdc3-4da6-bf4b-807044163756",
  "title": "Research Synthesis: Longevity Lifespan Subgroups \u2014 full paper"
}